Cefa-iskia en es it fr

Cefa-iskia Brand names, Cefa-iskia Analogs

Cefa-iskia Brand Names Mixture

  • No information avaliable

Cefa-iskia Chemical_Formula

C16H17N3O4S

Cefa-iskia RX_link

http://www.rxlist.com/cgi/generic/cephalex.htm

Cefa-iskia fda sheet

Cefa-iskia FDA

Cefa-iskia msds (material safety sheet)

Cefa-iskia MSDS

Cefa-iskia Synthesis Reference

R. B. Morin, B. G. Jackson, U.S. Pat. 3,275,626,861 (1966,1970)

Cefa-iskia Molecular Weight

347.39 g/mol

Cefa-iskia Melting Point

326.8oC

Cefa-iskia H2O Solubility

1789 mg/L

Cefa-iskia State

Solid

Cefa-iskia LogP

0.019

Cefa-iskia Dosage Forms

Capsules (containing cephalexin monohydrate equivalent to 250 mg or 500 mg cephalexin); Tablet (containing cephalexin monohydrate equivalent to 250 mg or 500 mg of cephalexin); Suspension

Cefa-iskia Indication

For the treatment of respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes; otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Moraxella catarrhalis; skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes; bone infections caused by Staphylococcus aureus and/or Proteus mirabilis; genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae.

Cefa-iskia Pharmacology

Cephalexin (also called Cefalexin) is a first generation cephalosporin antibiotic. It is one of the most widely prescribed antibiotics, often used for the treatment of superficial infections that result as complications of minor wounds or lacerations. It is effective against most gram-positive bacteria.

Cefa-iskia Absorption

Well absorbed from the gastrointestinal tract

Cefa-iskia side effects and Toxicity

Symptoms of overdose include blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting. The oral median lethal dose of cephalexin in rats is >5000 mg/kg.

Cefa-iskia Patient Information

Patients should be counseled that antibacterial drugs including Keflex should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Keflex is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Keflex or other antibacterial drugs in the future.

Cefa-iskia Organisms Affected

Enteric bacteria and other eubacteria